Empyrean Capital Partners LP Has $9.52 Million Stock Position in Oaktree Acquisition Corp. III Life Sciences $OACC

Empyrean Capital Partners LP boosted its stake in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) by 20.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 900,000 shares of the company’s stock after buying an additional 150,000 shares during the period. Empyrean Capital Partners LP owned approximately 4.01% of Oaktree Acquisition Corp. III Life Sciences worth $9,522,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Radcliffe Capital Management L.P. grew its position in shares of Oaktree Acquisition Corp. III Life Sciences by 175.5% during the 3rd quarter. Radcliffe Capital Management L.P. now owns 225,662 shares of the company’s stock worth $2,372,000 after purchasing an additional 143,749 shares in the last quarter. Berkley W R Corp grew its position in shares of Oaktree Acquisition Corp. III Life Sciences by 125.2% during the 3rd quarter. Berkley W R Corp now owns 223,645 shares of the company’s stock worth $2,351,000 after purchasing an additional 124,315 shares in the last quarter. Verition Fund Management LLC grew its position in shares of Oaktree Acquisition Corp. III Life Sciences by 6.7% during the 3rd quarter. Verition Fund Management LLC now owns 161,740 shares of the company’s stock worth $1,693,000 after purchasing an additional 10,117 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Oaktree Acquisition Corp. III Life Sciences during the 2nd quarter worth approximately $2,094,000. Finally, Meteora Capital LLC grew its position in shares of Oaktree Acquisition Corp. III Life Sciences by 402.0% during the 3rd quarter. Meteora Capital LLC now owns 248,500 shares of the company’s stock worth $2,612,000 after purchasing an additional 199,000 shares in the last quarter.

Oaktree Acquisition Corp. III Life Sciences Price Performance

Shares of NASDAQ:OACC opened at $10.67 on Thursday. The firm has a 50 day simple moving average of $10.68 and a 200 day simple moving average of $10.65. Oaktree Acquisition Corp. III Life Sciences has a one year low of $10.30 and a one year high of $10.74.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last issued its quarterly earnings data on Thursday, March 26th. The company reported $0.08 EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a report on Thursday, April 2nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Company Profile

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.